Interpace Biosciences, Inc. (NASDAQ:IDXG)
About the company
Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|IQVIA Holdings, Inc.||IQV||30169.26||11158.00||5.25||139.79||1.93|
|Laboratory Corp. of America Holdings||LH||18497.50||11587.00||2.61||58.62||2.77|
|Quest Diagnostics, Inc.||DGX||16624.64||7726.00||2.89||19.46||10.33|
|Syneos Health, Inc.||SYNH||6516.88||4720.00||2.15||33.05||4.13|
|National Research Corp.||NRC||1559.48||130.00||40.53||42.84||27.51|
|Apollo Medical Holdings, Inc.||AMEH||600.48||625.00||3.01||33.36||2.89|
|Protalix Biotherapeutics, Inc.||PLX||52.50||66.00||-3.68||-5.56||-14.18|
|Bioanalytical Systems, Inc.||BASI||51.70||55.00||5.16||-22.38||-3.94|
|Interpace Biosciences, Inc.||IDXG||20.08||27.00||2.97||-0.58||-121.14|
|Pressure BioSciences, Inc.||PBIO||4.50||2.00||-0.52||-0.28||-876.69|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
10/22/2019 N/A S-8 POS Registration Statement 04/30/2018 N/A S-8 Registration Statement 06/13/2017 N/A S-1/A Registration Statement * 06/13/2017 N/A S-1/A Registration Statement * 06/07/2017 N/A S ...
Today's Daily Dose brings you news about BioLife Solutions' preliminary second-quarter revenue estimate; Immunomedics' ...
Interpace Biosciences, Inc. (NASDAQ:IDXG) Q1 2020 Earnings Conference Call June 25, 2020 4:30 PM ET Company Participants Jack Stover - President and CEO Fred Knechtel - CFO Conference Call ...
PARSIPPANY, NJ, June 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) today announced financial results for the fiscal quarter ended March 31, 2020 and provided a business and ...
Interpace Biosciences, Inc. (NASDAQ:IDXG) shares rose 17.91% to $5.20. The most recent rating by HC Wainwright & Co., on Jun 26, is at Buy, with a price target of $11. • Chembio Diagnostics ...
3. Interpace Biosciences On Fire Interpace Biosciences Inc. (IDXG) has developed COVIANT, a qualitative blood test for the detection of IgG antibodies against SARS-CoV-2 in human plasma and serum.
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced financial results for the fiscal quarter ended March 31, 2020 and provided a business and financial update. “First quarter revenue was ...